Story perspectives

Promising Prostate Cancer Treatment Cuts PSA by 90%

2/28/2026

Center

De Bono's Breakthrough Treatment

In the PanTHa trial led by Professor Johann de Bono, 225Ac-PSMA-Trillium reduced PSA in 83% of 50 men.
Among those, 58% experienced a 90% drop.
The treatment aims to deliver radiation directly to cancer cells and may overcome treatment resistance.
Prostate cancer remains the most prevalent cancer in the UK, with 65,000 diagnoses annually.
Experts say innovative therapies are needed as hormone treatments dwindle, and further research seeks to improve outcomes.

Left

VIR-5500 Tumor Shrinkage

Early-stage trials of the immunotherapy drug VIR-5500 for advanced prostate cancer show tumor shrinkage in patients.
The drug is designed to activate only at tumor sites to minimize side effects.
In a trial of 58 men, 45% experienced tumor shrinkage.
88% reported only mild side effects.
Experts are optimistic about VIR-5500's potential, with 82% of highest-dose patients seeing PSA drops by at least half and further clinical trials planned.

1 of 2

De Bono's Breakthrough Treatment

In the PanTHa trial led by Professor Johann de Bono, 225Ac-PSMA-Trillium reduced PSA in 83% of 50 men.
Among those, 58% experienced a 90% drop.
The treatment aims to deliver radiation directly to cancer cells and may overcome treatment resistance.
Prostate cancer remains the most prevalent cancer in the UK, with 65,000 diagnoses annually.
Experts say innovative therapies are needed as hormone treatments dwindle, and further research seeks to improve outcomes.

1 / 2